Abstract
Tumor-associated macrophages (TAMs) contribute to breast cancer progression and dissemination; TAM-targeting strategies aimed at their reprogramming show promising preclinical results. In a new report Guerriero and colleagues demonstrate that a novel HDAC Class IIa inhibitor, TMP195, can reprogram monocytes and macrophages in the tumor into cells able to sustain a robust CD8 T cell-mediated anti-tumoral immune response.
MeSH terms
-
Animals
-
Benzamides / therapeutic use*
-
Breast Neoplasms* / drug therapy
-
Breast Neoplasms* / immunology
-
CD8-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / pathology
-
Cellular Reprogramming / drug effects*
-
Cellular Reprogramming / immunology
-
Female
-
Histone Deacetylase Inhibitors / therapeutic use*
-
Humans
-
Macrophages / immunology*
-
Macrophages / pathology
-
Monocytes / immunology
-
Monocytes / pathology
-
Oxadiazoles / therapeutic use*
Substances
-
Benzamides
-
Histone Deacetylase Inhibitors
-
Oxadiazoles
-
TMP195